Medical Research
(H12)
IRS Verified
DX Registered
990 on File
TO CURE A ROSE FOUNDATION
Financial strength (30%)
80/100
Reliability (20%)
40/100
Effectiveness (25%)
90/100
Impact (25%)
55/100
CharityAI™ Score
Not yet evaluated
Mission Statement
To Cure A Rose is one of only a few nonprofits focused first and foremost on drug development for rare genetic diseases. We understand the systemic and financial obstacles that block progress in precision medicine and have created pathways for families who seek answers now. The TCAR process offers rapid diagnosis, research and therapeutic drug development for families in need.
Financial Overview — FY 2024
$401K
Total Revenue
$427K
Total Expenses
$178K
Net Assets
4
Employees
Revenue Sources
Expense Breakdown
Program Expense Ratio
80.1%
Fundraising Efficiency
0.0%
Operating Reserve
5.01x
Liability-to-Asset
0.5%
Revenue Diversification
74.0%
Executive Compensation
$0
Compared with Peers
FY 2024
Compared with 726 similar organizations
(United States, Medical Research, $100K–$1M in expenses), FY 2024.
This organization
Middle half of peers (P25–P75)
Peer median
| Ratio | This org | Peer median | Position (P10 → P90) | |
|---|---|---|---|---|
|
Program expense ratio
Program expenses / total expenses
· higher is better
|
80.1% | 84.5% |
P10P90
|
Below median |
|
Admin expense ratio
Management and general / total expenses
· lower is better
|
19.9% | 11.4% |
P10P90
|
Below median |
|
Fundraising expense ratio
Fundraising expenses / total expenses
· lower is better
|
0.0% | 0.0% |
P10P90
|
Top quarter |
|
Fundraising efficiency
Fundraising expenses / gross fundraising income
· lower is better
|
0.0% | 10.0% |
P10P90
|
Top quarter |
|
Operating reserve
Months of expenses covered by net assets
· higher is better
|
5.0 mo | 13.4 mo |
P10P90
|
Below median |
|
Liabilities to assets
Total liabilities / total assets
· lower is better
|
0.5% | 0.4% |
P10P90
|
Below median |
|
Revenue concentration
Share of revenue from the largest source
· lower is better
|
74.0% | 93.3% |
P10P90
|
Above median |
|
Revenue growth
Year over year revenue growth
|
-18.4% | 9.1% |
P10P90
|
|
|
Expense growth
Year over year expense growth
|
8.6% | 8.8% |
P10P90
|
|
|
Surplus margin
Surplus as a share of revenue
|
-6.3% | 1.8% |
P10P90
|
Impact
1 program| Outcome / Program | People Served | Cost / Service | # Completed | Duration |
|---|---|---|---|---|
| mitigation of symptoms to cured | 1,000 | $65,000.00 | — | Lifetime |
Financial History
| Year | Revenue | Expenses | Net Assets | Program % | Staff |
|---|---|---|---|---|---|
| 2024 | $401K | $427K | $178K | 80.1% | 4 |
| 2023 | $492K | $393K | $203K | 91.4% | 4 |
| 2022 | $323K | $348K | $105K | 83.9% | 3 |
| 2021 | $430K | $85K | N/A | — | 0 |
Donor Reviews
Write a ReviewNo reviews yet
Be the first to share your experience with this organization.